Zheng Zhang

发表

Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes

Saijuan Chen, Lanping Xu, Xiao Li, 2016, Tumor Biology.

The biological behavior of SDF-1/CXCR4 in patients with myelodysplastic syndrome

Xiao Li, Chun-kang Chang, Feng Xu, 2012, Medical Oncology.

Exploration of the role of gene mutations in myelodysplastic syndromes through a sequencing design involving a small number of target genes

Xiao Li, Chun-kang Chang, Feng Xu, 2017, Scientific Reports.

Somatic mutations of activated signaling genes, transcription factors, or tumor suppressors are a precondition for leukemic transformation from myelodysplastic syndromes: a sequencing analysis of 64 paired samples

Xiao Li, Chun-kang Chang, Feng Xu, 2021, bioRxiv.

A genetic development route analysis on MDS subset carrying initial epigenetic gene mutations

Xiao Li, Chun-kang Chang, Feng Xu, 2020, Scientific Reports.

Integration Analysis of JAK2 or RUNX1 Mutation With Bone Marrow Blast Can Improve Risk Stratification in the Patients With Lower Risk Myelodysplastic Syndrome

Chun-kang Chang, Juan Guo, Lingyun Wu, 2021, Frontiers in Oncology.

Identification of microRNA-regulated pathways using an integration of microRNA-mRNA microarray and bioinformatics analysis in CD34+ cells of myelodysplastic syndromes

Yang Zhu, Xiao Li, Chun-kang Chang, 2016, Scientific Reports.

Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome

Ling Wu, Yang Zhu, Xiao Li, 2014, Scientific Reports.

Establishment and Validation of an Updated Diagnostic FCM Scoring System Based on Pooled Immunophenotyping in CD34+ Blasts and Its Clinical Significance for Myelodysplastic Syndromes

Yang Zhu, Xiao Li, Chun-kang Chang, 2014, PloS one.

Over-expression of RPL23 in myelodysplastic syndromes is associated with apoptosis resistance of CD34+ cells and predicts poor prognosis and distinct response to CHG chemotherapy or decitabine

Yan Zhang, Xiao Li, Chun-kang Chang, 2012, Annals of Hematology.

Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome

Xiao Li, Chun-kang Chang, Juan Guo, 2021, Clinical Epigenetics.

Decitabine treatment sensitizes tumor cells to T-cell-mediated cytotoxicity in patients with myelodysplastic syndromes.

Xiao Li, Chun-kang Chang, Juan Guo, 2017, American journal of translational research.

Somatic mutations in SF3B1 aberrant‐negative MDS‐RS most commonly involved in TP53 genes

Xiao Li, Juan Guo, Lingyun Wu, 2022, Journal of cellular and molecular medicine.

Low RPS14 expression in MDS without 5q ‐ aberration confers higher apoptosis rate of nucleated erythrocytes and predicts prolonged survival and possible response to lenalidomide in lower risk non‐5q‐ patients

Xiao Li, Chun-kang Chang, Lingyun Wu, 2013, European journal of haematology.

Flow cytometric scoring system (FCMSS) assisted diagnosis of myelodysplastic syndromes (MDS) and the biological significance of FCMSS‐based immunophenotypes

Xiao Li, Chun-kang Chang, Lingyun Wu, 2010, British journal of haematology.

Iron overload promotes erythroid apoptosis through regulating HIF-1a/ROS signaling pathway in patients with myelodysplastic syndrome.

Sida Zhao, Xiao Li, Chun-kang Chang, 2017, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

Interleukin‐17 enhances the production of interferon‐γ and tumour necrosis factor‐α by bone marrow T lymphocytes from patients with lower risk myelodysplastic syndromes

Yan Zhang, Xiao Li, Chun-kang Chang, 2013, European journal of haematology.

Decitabine Induces Change of Biological Traits in Myelodysplastic Syndromes via FOXO1 Activation

Yan Jia, Chun-kang Chang, Juan Guo, 2020, Frontiers in Genetics.

Diagnostic application and clinical significance of FCM progress scoring system based on immunophenotyping in CD34+ blasts in myelodysplastic syndromes

Xiao Li, Chun-kang Chang, Juan Guo, 2013, Cytometry. Part B, Clinical cytometry.

Distinct Clinical and Experimental Characteristics in the Patients Younger than 60 Years Old with Myelodysplastic Syndromes

Z. Xiao, Xiao Li, Chun-kang Chang, 2013, PloS one.

Overexpression of BMI1 confers clonal cells resistance to apoptosis and contributes to adverse prognosis in myelodysplastic syndrome.

Xiao Li, Chun-kang Chang, Juan Guo, 2012, Cancer letters.

TP53 mutations predict decitabine‐induced complete responses in patients with myelodysplastic syndromes

Xiao Li, Chun-kang Chang, Juan Guo, 2017, British journal of haematology.

Comparison of immunological abnormalities of lymphocytes in bone marrow in myelodysplastic syndrome (MDS) and aplastic anemia (AA).

Xiao Li, Chun-kang Chang, Lingyun Wu, 2010, Internal medicine.

A delayed yet durable response to very short lenalidomide therapy and unexpected clone redistribution in a case of myelodysplastic syndrome with del(5q) and del(20q).

Xiao Li, Chun-kang Chang, Lingyun Wu, 2009, Leukemia research.

Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndrome

Yang Zhu, Xiao Li, Chun-kang Chang, 2016, Oncotarget.

Aryl hydrocarbon receptor signaling pathway plays important roles in the proliferative and metabolic properties of bone marrow mesenchymal stromal cells.

Yan Jia, Chun-kang Chang, Zheng Zhang, 2021, Acta biochimica et biophysica Sinica.

Somatic mutations of activating signalling, transcription factor, and tumour suppressor are a precondition for leukaemia transformation in myelodysplastic syndromes

Xiao Li, Juan Guo, Lingyun Wu, 2022, Journal of cellular and molecular medicine.

Initial characterization of immune microenvironment in pheochromocytoma and paraganglioma

Jingcheng Zhou, Y. Gong, Zheng Zhang, 2022, Frontiers in Genetics.

Whole-exome and targeted sequencing identify ROBO1 and ROBO2 mutations as progression-related drivers in myelodysplastic syndromes

Yang Zhu, Xiao Li, Chun-kang Chang, 2015, Nature Communications.

MYCN contributes to the malignant characteristics of erythroleukemia through EZH2-mediated epigenetic repression of p21

Xiao Li, Chun-kang Chang, Li Liu, 2017, Cell Death & Disease.

IGF-IR promotes clonal cell proliferation in myelodysplastic syndromes via inhibition of the MAPK pathway

Sida Zhao, Xiao Li, Chun-kang Chang, 2020, Oncology reports.

Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring

Xiao Li, Chun-kang Chang, Lingyun Wu, 2011, Annals of Hematology.

AHR signaling pathway reshapes the metabolism of AML/MDS cells and potentially leads to cytarabine resistance.

Yan Jia, Chun-kang Chang, Juan Guo, 2021, Acta biochimica et biophysica Sinica.

Downregulation of p21 in myelodysplastic syndrome is associated with p73 promoter hypermethylation and indicates poor prognosis.

Xiao Li, Chun-kang Chang, Juan Guo, 2013, American journal of clinical pathology.

Cytogenetic response based on revised IPSS cytogenetic risk stratification and minimal residual disease monitoring by FISH in MDS patients treated with low-dose decitabine.

Xiao Li, Chun-kang Chang, Lingyun Wu, 2013, Leukemia research.

The efficacy and toxicity of the CHG priming regimen (low-dose cytarabine, homoharringtonine, and G-CSF) in higher risk MDS patients relapsed or refractory to decitabine

Xiao Li, Chun-kang Chang, Y. Tao, 2019, Journal of Cancer Research and Clinical Oncology.

Decitabine of Reduced Dosage in Chinese Patients with Myelodysplastic Syndrome: A Retrospective Analysis

Q. Song, M. Hou, Xiao Li, 2014, PloS one.

Cytogenetic Response Based On Revised IPSS Cytogenetic Risk Stratification and Minimal Residual Disease Monitoringby FISH In MDS Patients Treated By Low-Dose Decitabine

Chun-kang Chang, Lingyun Wu, Dong-dong Wu, 2013 .

Identification of prognostic genes in adrenocortical carcinoma microenvironment based on bioinformatic methods

Zicheng Xu, Xiao Li, Feng Qi, 2019, Cancer medicine.

Aberration of p73 promoter methylation in de novo myelodysplastic syndrome

Xiao Li, Chun-kang Chang, Juan Guo, 2012, Hematology.

The effect of the combination of bisphosphonates and conventional chemotherapy on bone metabolic markers in multiple myeloma patients

Xiao Li, Chun-kang Chang, Lingyun Wu, 2012, Hematology.

High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome

Xiao Li, Chun-kang Chang, Wenhui Shi, 2016, Journal of Translational Medicine.

U2AF1 mutation promotes tumorigenicity through facilitating autophagy flux mediated by FOXO3a activation in myelodysplastic syndromes

Yuqian Zhu, Xiao Li, Chun-kang Chang, 2021, Cell Death & Disease.

Increased PD-1/STAT1 ratio may account for the survival benefit in decitabine therapy for lower risk myelodysplastic syndrome

Xiao Li, Chun-kang Chang, Juan Guo, 2017, Leukemia & lymphoma.

Bone Marrow Fibrosis at Diagnosis and during the Course of Disease Is Associated with TP53 Mutations and Adverse Prognosis in Primary Myelodysplastic Syndrome

Sida Zhao, Zheng Zhang, Chun-kang Chang, 2022, Cancers.

Decreased FOXO1 Expression Is Correlated with Poor Prognosis in Myelodysplastic Syndromes

Sida Zhao, Chun-kang Chang, Juan Guo, 2022, Current oncology.

Overexpression of IGF-IR in Malignant Clonal Cells in Bone Marrow of Myelodysplastic Syndromes

Xiao Li, Y. Tao, Yi-zhi Liu, 2010, Cancer investigation.

A genetic development route analysis on MDS subset carrying initial epigenetic gene mutations

Xiao Li, Chun-kang Chang, Juan Guo, 2020, Scientific Reports.

DHX9-mediated pathway contributes to the malignant phenotype of myelodysplastic syndromes

Xiao Li, Juan Guo, Wenhui Shi, 2023, iScience.

Down-regulation of Dicer1 promotes cellular senescence and decreases the differentiation and stem cell-supporting capacities of mesenchymal stromal cells in patients with myelodysplastic syndrome

Yang Zhu, Xiao Li, Chun-kang Chang, 2015, Haematologica.

High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome

Qi He, Feng Xu, Lingyun Wu, 2016, Journal of Translational Medicine.

Efficacy and toxicity of decitabine versus CHG regimen (low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor) in patients with higher risk myelodysplastic syndrome: a retrospective study

Xiao Li, Chun-kang Chang, Lingyun Wu, 2016, Leukemia & lymphoma.

Whole-exome and targeted sequencing identify ROBO1 and ROBO2 mutations as progression-related drivers in myelodysplastic syndromes

Yang Zhu, Xiao Li, Chun-kang Chang, 2015, Nature Communications.

ROBO1 deficiency impairs HSPC homeostasis and erythropoiesis via CDC42 and predicts poor prognosis in MDS.

Cheng-Long Hu, Juan Guo, Lingyun Wu, 2023, Science Advances.

NPM1 mutation with DNMT3A wild type defines a subgroup of MDS with particularly favourable outcomes after decitabine therapy

Xiao Li, Chun-kang Chang, Juan Guo, 2020, British Journal of Haematology.